As a world-leading service provider of antibody development and generation, Creative Biolabs is ready to provide a whole series of biomarker-specific in vitro diagnostic (IVD) antibody development services. Here, we introduce our IVD antibody development services targeting protein S-100β marker. A team of experienced scientists focused on antibody development are pleased to assist you in your project in a timely and cost-effective manner.
Protein S-100β
S100 calcium-binding protein β (S100β) belongs to the S-100 protein family. It is localized in the cytoplasm and nucleus of a wide range of cells and involved in the regulation of a number of cellular processes including cell cycle progression and differentiation. S100β is glial-specific and is expressed primarily by astrocytes, but not all astrocytes express S100β. In the developing CNS, S100β acts as a neurotrophic factor and a neurosurvival protein. In adult organisms, it usually rises due to nervous system damage, which makes it a potential clinical marker.
S100β is secreted by astrocytes or can spill from injured cells and enter the extracellular space or bloodstream. Serum levels of S100β increase in patients during the acute phase of brain damage. Over the past decade, S100β has become a candidate peripheral biomarker of blood-brain barrier permeability and CNS injury. Increased levels of S100β accurately reflect the presence of neuropathological conditions, including neurodegenerative diseases or traumatic head injury.
Fig. 1 Structure of the S100β protein.1
Protein S-100β Marker of Sepsis Infections
Septic encephalopathy (SE) is a common but not well-understood complication of sepsis that affects between 9% and 71% of septic patients, depending on the diagnostic criteria used. SE may be defined as a cerebral disorder resulting from metabolic and cellular signaling changes that are mediated by inflammatory components SE is typically an early event during the natural evolution of the disease and often appears prior to the failure of other organs. Moreover, SE is associated with a worse prognosis. It is found that S100β can be used as a promising biomarker for diagnosing and monitoring patients with SE.
IVD Antibody Development Services Targeting Protein S-100β
IVD antibodies have been widely used for disease screening and therapeutic monitoring. As a research partner with years of experience in high-quality antibody development and production, Creative Biolabs offers one-stop solutions from antigen design to antibody pair screening. Besides, we also offer diagnostic immunoassay development services, including feasibility analysis, assay design, assay protocol establishment, assay optimization, and kit production.
If you are interested in our IVD antibody development services, please feel free to contact us for more details.
Reference
For Research Use Only.
